Dianthus Therapeutics, Inc. /DE/ - 8-K Filing
Dianthus Therapeutics held its annual stockholder meeting on May 21, 2026, where Sujay Kango, Anne McGeorge, and Jonathan Violin were elected as Class II directors; shareholders approved executive compensation with 41.0 million votes in favor versus 1.7 million against; and ratified Deloitte & Touche LLP as the independent auditor for fiscal year ending December 31, 2026. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $DNTH